The authors also reported that G1 inhibited tumor growth of HCC xenografts by activating GPER/EGFR/ERK signaling [154], indicating that the pharmacological activation of GPER could be a viable therapeutic strategy for HCC patients. The gene discussed is MAPK1; the disease is hepatocellular carcinoma.